You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

CLINICAL TRIALS PROFILE FOR TNKASE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TNKASE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed Eli Lilly and Company Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed Hoffmann-La Roche Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed Sanofi Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed University of Alberta Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TNKASE

Condition Name

Condition Name for TNKASE
Intervention Trials
Myocardial Infarction 2
Elevated IMR (>32) 1
Ischemic Stroke 1
Pleural Effusion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TNKASE
Intervention Trials
Stroke 3
Myocardial Infarction 3
ST Elevation Myocardial Infarction 2
Ischemic Stroke 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TNKASE

Trials by Country

Trials by Country for TNKASE
Location Trials
Canada 5
China 5
Australia 4
United States 4
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TNKASE
Location Trials
California 2
Ohio 1
Hawaii 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TNKASE

Clinical Trial Phase

Clinical Trial Phase for TNKASE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TNKASE
Clinical Trial Phase Trials
Recruiting 2
Terminated 2
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TNKASE

Sponsor Name

Sponsor Name for TNKASE
Sponsor Trials
Genentech, Inc. 3
Sanofi 1
Cedars-Sinai Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TNKASE
Sponsor Trials
Other 15
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.